Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Wednesday, April 23, 2025

View Back issues

Securities Class

SAN FRANCISCO – Shareholders must amend claims that Amyris Inc. and its CEO John Melo knowingly misrepresented production levels of the chemical product Biofene.

Categories / Uncategorized

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.

Loading...